China No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered approvals for its therapies Brukinsa and Tevimbra. The company is on a growth trajectory with product sales reaching USD 2.2…
China A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’ stock plunge, and BeiGene’s USD 1.33 billion CDK2 inhibitor deal with Ensem Therapeutics. Bristol Myers to pay $800 million…
Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility. Johnson & Johnson Innovation…
China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…
China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…
USA In the current economic environment companies are faced with increased pressure to manage cash and meet investor expectations with tightened budgets. Life science industry CFOs, as a recent survey and webinar reveal, are looking to preserve and generate cash by making their companies more efficient and building partnerships while confronting…
China Perhaps Chinese biotech’s biggest success story, cancer-focused Beigene has evolved from the commitment of founders John Oyler and Xiaodong Wang to conducting clinical research in China with a global outlook. Fresh from recent announcements of an IPO in Shanghai to add to listings on NASDAQ and in Hong Kong and…
China The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan Yang who is aiming to produce the first pig organs that can be successfully transplanted into humans; and the Republican…
Hong Kong On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies have seized the opportunity to IPO under the new Chapter 18A, raising a total of over HKD 34.92 billion (USD…
See our Cookie Privacy Policy Here